Rticc
Seleccione idioma:  
Buscar:
RTICC 2013
Programas RTICC
Agenda
Seguimiento cientifico
Sobre la RTICC 2013-2016 » Organización
 
ORGANIZATION AND MANAGEMENT

The experience of the two previous editions of our Spanish Cancer Research Networks (RTICCC and RTICC) has greatly helped in defining additional new criteria used in this proposal to fully define the structure, organization and management of the currently proposed cancer RETIC for the period 2013-2016 that should facilitate a better integration and increase of the collaborative cancer research efforts in our country and a measurable improvement of its quality and international competitiveness.

In comparison to previous RTICC editions, some of the new organizational details comprised in the current proposal for a new cancer RETIC involve new requisites or constraints regarding a minimal size of the research groups (at least 4stable staff investigators), the emphasis on translational and specific tumor-oriented research, the minimum/maximum size established for the research programs (each, min 6, max.15 groups) or the requirement for at least 50% of the groups in the overall network to carry out its cancer research in clinical settings.

Following those general criteria, the structure, organization and function of the future RETIC on cancer will revolve around several KEY SCIENTIFIC AND MANAGERIAL INSTRUMENTS, as follows:

ORGANIGRAMA
Bienvenida
Organización
Presentación
Objetivos
Work Packages
Intranet
Directorio
Coordinación RTICC
Noticias
03/03/2017 | Otras reuniones
13/11/2016 | Otras reuniones
Publicaciones
RD12/0036/0023
NOTCH1, TP53, and MAP2K1 Mutations in Splenic Diffuse Red Pulp Small B-cell Lymphoma Are Associated With Progressive Disease.
Martinez D, Navarro A, Martinez-Trillos A, Molina-Urra R, Gonzalez-Farre B, Salaverria I, Nadeu F, Enjuanes A, Clot G, Costa D, Carrio A, Villamor N, Colomer D, Martinez A, Bens S, Siebert R, Wotherspoon A, Beà S, Matutes E, Campo E
Am J Surg Pathol  2016.  2.  192-201.  PMID: 26426381. 
Grupos colaboradores: RD12/0036/0036 , RD12/0036/0023

RD12/0036/0023
Present and future of personalized medicine in CLL.
Montserrat E, Bauman T, Delgado J
Best Pract Res Clin Haematol  2016.  1.  100-110.  PMID: 27742064. 

RD12/0036/0023
Maintenance therapy in chronic lymphocytic leukaemia.
Delgado J, Montserrat E
Lancet Haematol  2016.  9.  e399-400.  PMID: 27570083. 

RD12/0036/0023
[Advances in the treatment of chronic lymphocytic leukaemia].
Mozas P, Delgado J
Med Clin (Barc)  2016.  10.  447-454.  PMID: 27431885. 

RD12/0036/0023
The biology behind B-cell lymphoma 2 as a target in chronic lymphocytic leukemia.
Ortíz-Maldonado V, Mozas P, Delgado J
Ther Adv Hematol  2016.  6.  321-329.  PMID: 27904736. 

RD12/0036/0023
The European Hematology Association Roadmap for European Hematology Research: a consensus document.
Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, de Wit TD, Eichinger S, Fibbe W, Green T, de Haas F, Iolascon A, Jaffredo T, Rodeghiero F, Salles G, Schuringa JJ, EHA Roadmap for European Hematology Research.
Haematologica  2016.  2.  115-208.  PMID: 26819058. 

RD12/0036/0023
Diffuse Large B-Cell Lymphoma: Should Limited-Stage Patients Be Treated Differently?
Giné E, Sehn LH
Hematol Oncol Clin North Am  2016.  6.  1179-1194.  PMID: 27888874. 

RD12/0036/0023
Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage.
Queirós AC, Beekman R, Vilarrasa-Blasi R, Duran-Ferrer M, Clot G, Merkel A, Raineri E, Russiñol N, Castellano G, Beà S, Navarro A, Kulis M, Verdaguer-Dot N, Jares P, Enjuanes A, Calasanz MJ, Bergmann A, Vater I, Salaverría I, van de Werken HJ, Wilson WH, Datta A, Flicek P, Royo R, Martens J, Giné E, Lopez-Guillermo A, Stunnenberg HG, Klapper W, Pott C, Heath S, Gut IG, Siebert R, Campo E, Martín-Subero JI
Cancer Cell  2016.  5.  806-821.  PMID: 27846393. 
Grupos colaboradores: RD12/0036/0063 , RD12/0036/0036 , RD12/0036/0023

RD12/0036/0023
Genetic evolution in chronic lymphocytic leukaemia.
Delgado J, Villamor N, López-Guillermo A, Campo E
Best Pract Res Clin Haematol  2016.  1.  67-78.  PMID: 27742073. 
Grupos colaboradores: RD12/0036/0036 , RD12/0036/0023

RD12/0036/0020
FEMALE NEWBORN WITH UNDIFFERENTIATED SARCOMA DEFINED BY BCORCCNB3 FUSION TRANSCRIPT
Martín-Vañó S, Berbegall AP, Navarro L, Blanquer-Maceiras M, Beléndez-Bieler C, Garrido-Colino C, Navarro S, Rosa Noguera Salvá
  2015. 

ISCII
ISCII
 
Ministerio de Economia y Competitividad
Descargar
Red Temática Investigación Cooperativa Sanitaria
Rticc 2012
Logotipos
 
ISCII
Red Temática Investigación Cooperativa en Cáncer (RTICC)
Centro de Investigación Cáncer - Campus Miguel de Unamuno - 37007 - Salamanca
(+34) 923294803 - sec.rticc[arroba]usal.es
|
|
|
|
 
Sobre la RTICC Programas RTICC Ofertas de empleo y Agenda Seguimiento científico
Red Temática de Investigación Cooperativa en Cáncer · © Copyright 2013 · sec.rticc[arrroba]usal.es · diseño web: detrazos
RSS